Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Stock Performance

Shares of Eli Lilly and stock traded down $4.47 during trading on Friday, hitting $301.32. 2,814,275 shares of the stock were exchanged, compared to its average volume of 2,491,261. The stock has a market capitalization of $286.30 billion, a price-to-earnings ratio of 48.06, a price-to-earnings-growth ratio of 2.23 and a beta of 0.35. The company has a fifty day moving average price of $316.10 and a 200-day moving average price of $289.32. Eli Lilly and has a 1-year low of $220.20 and a 1-year high of $335.33. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60.

Eli Lilly and (NYSE:LLY - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion for the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a return on equity of 85.10% and a net margin of 19.58%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.87 earnings per share. As a group, equities analysts predict that Eli Lilly and will post 7.98 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Friday, August 12th. Eli Lilly and's payout ratio is 62.52%.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. SVB Leerink began coverage on shares of Eli Lilly and in a research note on Monday, May 23rd. They issued an "outperform" rating and a $341.00 price objective on the stock. UBS Group raised their price objective on shares of Eli Lilly and to $335.00 and gave the company an "outperform" rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Wells Fargo & Company lifted their price target on shares of Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. Finally, Mizuho lifted their price target on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and has an average rating of "Moderate Buy" and a consensus price target of $316.06.

Insider Buying and Selling

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 80,761 shares of the business's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $302.53, for a total value of $24,432,625.33. Following the completion of the sale, the insider now owns 105,493,049 shares of the company's stock, valued at approximately $31,914,812,113.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,274 shares in the company, valued at approximately $1,966,522.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 80,761 shares of the business's stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $302.53, for a total transaction of $24,432,625.33. Following the completion of the transaction, the insider now owns 105,493,049 shares of the company's stock, valued at $31,914,812,113.97. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,195,396 shares of company stock valued at $380,134,601. Company insiders own 0.12% of the company's stock.